Steris (STE) Q1 Revenue Rises 8%
(NYSE:STE), a healthcare company specializing in infection prevention and sterilization products and services, reported Q1 FY2026 earnings on August 6, 2025. The most notable news from the release was that while the company delivered solid year-over-year growth and margin gains, both revenue (GAAP) and non-GAAP earnings per share (EPS) fell short of analyst expectations. Actual revenue (GAAP) reached $1,391.1 million, compared to an analyst estimate of $1,447.8 million, while adjusted EPS came in at $2.34 versus a consensus estimate of $2.47. But increased tariffs and higher employee benefit costs offset foreign currency gains, keeping the adjusted earnings per diluted share outlook unchanged despite a raised revenue forecast. Overall, the period featured robust operational performance but highlighted new cost challenges for the business.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q4 2025 earnings report.
Steris provides sterilization, infection prevention, and procedural support solutions for hospitals, surgery centers, and pharmaceutical manufacturers. Its core offerings include sterilizers, surgical tables, and endoscope reprocessors—products vital for maintaining safety in healthcare environments. The company earns a significant share of revenue through recurring services and consumable items, such as cleaning supplies and ongoing maintenance.
Source Fool.com
